A multicenter, double-blind trial assessed the efficacy of sotagliflozin, an SGLT2 inhibitor, when started soon after a heart failure episode in type 2 diabetes patients. Participants received sotagliflozin or placebo around the time of hospital discharge, aiming to track cardiovascular deaths, hospitalizations, and urgent heart failure visits. Despite an early end due to funding, the study followed 1222 patients for nine months and found fewer cardiovascular events in the sotagliflozin group compared to placebo.

The results indicated a significant drop in cardiovascular events for those on sotagliflozin, with 51.0 versus 76.3 events per 100 patient-years and a hazard ratio of 0.67. Although cardiovascular death rates were lower in the sotagliflozin group, they were not statistically significant. Overall, sotagliflozin initiated post-heart failure hospitalization led to better cardiovascular outcomes, showcasing its benefits for high-risk patients.

Reference: Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16. PMID: 33200892.